Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. (Q52072195)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2000

Language	Label	Description	Also known as
English	Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.	scientific article published in October 2000

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

17

object named as

C Blomqvist

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

15

object named as

H Holte

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

author name string

J Bergh

1

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

B Erikstein

3

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

E Lidbrink

4

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

H Lindman

5

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

P Malmström

6

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

P Kellokumpu-Lehtinen

7

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

N O Bengtsson

8

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

G Söderlund

9

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

G Anker

10

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

E Wist

11

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

S Ottosson

12

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

E Salminen

13

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

P Ljungman

14

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

J Nilsson

16

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

N Wilking

18

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

language of work or name

0 references

publication date

1 October 2000

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

356

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

9239

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

1384-1391

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Where next with stem-cell-supported high-dose therapy for breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetics-pharmacodynamics of anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tailored chemotherapy to equal toxicity: is it possible?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive criteria for assessing therapy-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute promyelocytic leukemia with t(15;17) following inhibition of DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(00)02841-5

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11052580

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52072195&oldid=1584681538"